Coloplast A/S

CLPBY | OTC

Price Alert Chart Builder DCF Calculator

$6.47

$0 (0.00%)

Sep 22, 2026, 1:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+0.00%

(1D)

Rating

Updated: Sep 14, 2026

38.5

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $14.58B

1D Range

6.44 6.54

52W Range

5.64 9.70

Valuation (TTM)

PE 33.96

PB 7.14

EV/EBITDA 9.86

Valuation (NTM)

Forward PE 15.85

Forward PEG 9.00

Price Target $7.38

Cash Flow

FCF Yield 6.6%

SBC Adj. FCF Yield 6.6%

SBC Impact N/A

Margins

Gross Margin 58.5%

Operating Margin 27.8%

FCF Margin 23.3%

Growth (CAGR)

Revenue 3Y | 5Y 3.6% | 7.4%

Dil EPS 3Y | 5Y -18.5% | -10.6%

FCF 3Y | 5Y 25.1% | 15.3%

Returns

ROA 5.9%

ROE 19.7%

ROIC 12.1%

Financial Health

Net Debt

kr22.27B ($3.4B)

Current Ratio 1.56

Interest Coverage 10.75

Dividends

Div Yield 5.56%

Payout Ratio 29.5%

FCF Payout Ratio 84.6%

All Key Statistics

Loading financial charts...

Profile

A detailed description of the company is not yet available.

Sector n/a

Industry n/a

Employees n/a

IPO Date n/a

Website n/a

Fiscal Year n/a

Full Company Profile

Latest News

1 month ago · seekingalpha.com

Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript

1 month ago · reuters.com

Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says

Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall sharply, its finance chief ‌told Reuters on Tuesday.

2 months ago · seekingalpha.com

Coloplast Might Have Found Its Bottom

Coloplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion Kerecis impairment and currency headwinds. Management guides for 5–6% organic revenue growth and 5% EBIT growth in FY25/26, but targets 7–8% annual organic growth and 20%+ ROIC by FY29/30.

Earnings

Next Earnings

Nov 3, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞